丝裂霉素C在激光泪道成形术中的疗效观察  

Efficacy Observation of Mitomycin C in Laser Lacryocystoplasty

作　　者：王淑莉[1] 黄宝玲[1] 陈瑞合[1] 

机构地区：[1]河南漯河市中心医院,漯河市462000

出　　处：《中国药房》2011年第30期2851-2853,共3页China Pharmacy

摘　　要：目的:观察丝裂霉素C在激光泪道成形术中的临床疗效。方法:泪道阻塞患者118例(162眼)随机分为2组,对照组58例(80眼)在激光泪道成形术后,将妥布霉素/地塞米松眼膏注入泪道,试验组60例(82眼)在激光泪道成形术后将0.2g·L-1丝裂霉素C溶液注入泪道并停留5min后,将妥布霉素/地塞米松眼膏注入泪道。观察2组的泪道是否通畅及有无丝裂霉素C的不良反应。结果:术后随访6～12个月,试验组与对照组的总有效率分别为91.5%、80.0%,差异有统计学意义(χ2=4.37,P<0.05)。随访中未发现丝裂霉素C的并发症。结论:在激光泪道成形术中,0.2g·L-1丝裂霉素C的应用是安全的,可提高手术的成功率。OBJECTIVE：To evaluate the clinical efficacy of mitomycin C in laser lacryocystoplasty.METHODS：118 cases （162 eyes） of lacrimal duct obstruction were randomly divided into two groups.58 cases （80 eyes） in control group received lacrimal duct irrigation of tobramycin/dexamethasone oculentum after laser lacryocystoplasty.60 cases （82 eyes） in test group were treated with mitomycin C 0.2 g·L-1 by lacrimal duct irrigation,5 minutes later treated with tobramycin/dexamethasone oculentum.The condition of lacrimal duct and mitomycin C induced ADR were observed in two groups.RESULTS：For 6～12 months follow-up after operation,the total effective rates of test group and control group were 91.5% and 80.0% respectively.There was statistical significant difference between two groups （χ2=4.37,P0.05）.The complication of mitomycin C hadn＇t been found during follow-up.CONCLUSION：Mitomycin C 0.2 g·L-1 is safe and effect for laser lacryocystoplasty and provides a higher successful rate.

关 键 词：丝裂霉素C 激光泪道 泪道阻塞 

分 类 号：R969.4[医药卫生—药理学] R988.1[医药卫生—药学]